First-line treatment with epirubicin and vinorelbine in metastatic breast cancer

Patrizia Vici, Giuseppe Colucci, Vittorio Gebbia, Antonella Amodio, Francesco Giotta, Franca Belli, Francesca Conti, Nicola Gebbia, Giuseppe Pezzella, Maria Rosaria Valerio, Mario Brandi, Salvatore Pisconti, Ernesto Durini, Diana Giannarelli, Massimo Lopez

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: This phase II multicenter trial was aimed at investigating the activity of epirubicin-vinorelbine combination as first-line chemotherapy in metastatic breast cancer patients. Patients and Methods: Ninety-seven patients with metastatic breast cancer and no prior exposure to anthracyclines received the following regimen: epirubicin 100 mg/m2 by intravenous (IV) bolus infusion on day 1 plus vinorelbine 25 mg/m2 by 30-minute IV infusion on days 1 and 5, every 3 weeks for up to eight cycles. All patients also received granulocyte colony-stimulating factor (G-CSF) on days 7 to 12 of every cycle. Results: Objective responses, confirmed at least 4 weeks after the first documentation, were observed in 65 out of 92 assessable patients (70.6%; 95% Cl, 62% to 80%). Disease remained stable in 17 patients (18.5%). Responses were observed in all disease sites, being 94% in soft tissue, 60% in bone, and 66% in visceral disease. Median time to response, median duration of response, median time to progression, and median overall survival were 2, 9, 10, and 26 months, respectively. The dose-limiting toxicity was neutropenia, which was grade 4 in 36% of the patients, and was accompanied by fever in 26% of the cases. Grade 3 to 4 mucositis was encountered in 28% of the patients. Other toxicities were mild to moderate. No cardiotoxicity was observed. Conclusion: The epirubicin-vinorelbine combination with G-CSF support has been shown in this study to be highly active as first-line treatment of metastatic breast cancer patients, with significant although transient toxicity. This justifies further evaluation in the neoadjuvant setting and in early-stage breast cancer.

Original languageEnglish
Pages (from-to)2689-2694
Number of pages6
JournalJournal of Clinical Oncology
Volume20
Issue number11
DOIs
Publication statusPublished - Jun 1 2002

Fingerprint

Epirubicin
Breast Neoplasms
Therapeutics
Granulocyte Colony-Stimulating Factor
Intravenous Infusions
vinorelbine
Mucositis
Anthracyclines
Neutropenia
Documentation
Multicenter Studies
Fever
Bone and Bones
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. / Vici, Patrizia; Colucci, Giuseppe; Gebbia, Vittorio; Amodio, Antonella; Giotta, Francesco; Belli, Franca; Conti, Francesca; Gebbia, Nicola; Pezzella, Giuseppe; Valerio, Maria Rosaria; Brandi, Mario; Pisconti, Salvatore; Durini, Ernesto; Giannarelli, Diana; Lopez, Massimo.

In: Journal of Clinical Oncology, Vol. 20, No. 11, 01.06.2002, p. 2689-2694.

Research output: Contribution to journalArticle

Vici, P, Colucci, G, Gebbia, V, Amodio, A, Giotta, F, Belli, F, Conti, F, Gebbia, N, Pezzella, G, Valerio, MR, Brandi, M, Pisconti, S, Durini, E, Giannarelli, D & Lopez, M 2002, 'First-line treatment with epirubicin and vinorelbine in metastatic breast cancer', Journal of Clinical Oncology, vol. 20, no. 11, pp. 2689-2694. https://doi.org/10.1200/JCO.2002.06.039
Vici, Patrizia ; Colucci, Giuseppe ; Gebbia, Vittorio ; Amodio, Antonella ; Giotta, Francesco ; Belli, Franca ; Conti, Francesca ; Gebbia, Nicola ; Pezzella, Giuseppe ; Valerio, Maria Rosaria ; Brandi, Mario ; Pisconti, Salvatore ; Durini, Ernesto ; Giannarelli, Diana ; Lopez, Massimo. / First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 11. pp. 2689-2694.
@article{38fadb8baacd4d879a6b972490305b14,
title = "First-line treatment with epirubicin and vinorelbine in metastatic breast cancer",
abstract = "Purpose: This phase II multicenter trial was aimed at investigating the activity of epirubicin-vinorelbine combination as first-line chemotherapy in metastatic breast cancer patients. Patients and Methods: Ninety-seven patients with metastatic breast cancer and no prior exposure to anthracyclines received the following regimen: epirubicin 100 mg/m2 by intravenous (IV) bolus infusion on day 1 plus vinorelbine 25 mg/m2 by 30-minute IV infusion on days 1 and 5, every 3 weeks for up to eight cycles. All patients also received granulocyte colony-stimulating factor (G-CSF) on days 7 to 12 of every cycle. Results: Objective responses, confirmed at least 4 weeks after the first documentation, were observed in 65 out of 92 assessable patients (70.6{\%}; 95{\%} Cl, 62{\%} to 80{\%}). Disease remained stable in 17 patients (18.5{\%}). Responses were observed in all disease sites, being 94{\%} in soft tissue, 60{\%} in bone, and 66{\%} in visceral disease. Median time to response, median duration of response, median time to progression, and median overall survival were 2, 9, 10, and 26 months, respectively. The dose-limiting toxicity was neutropenia, which was grade 4 in 36{\%} of the patients, and was accompanied by fever in 26{\%} of the cases. Grade 3 to 4 mucositis was encountered in 28{\%} of the patients. Other toxicities were mild to moderate. No cardiotoxicity was observed. Conclusion: The epirubicin-vinorelbine combination with G-CSF support has been shown in this study to be highly active as first-line treatment of metastatic breast cancer patients, with significant although transient toxicity. This justifies further evaluation in the neoadjuvant setting and in early-stage breast cancer.",
author = "Patrizia Vici and Giuseppe Colucci and Vittorio Gebbia and Antonella Amodio and Francesco Giotta and Franca Belli and Francesca Conti and Nicola Gebbia and Giuseppe Pezzella and Valerio, {Maria Rosaria} and Mario Brandi and Salvatore Pisconti and Ernesto Durini and Diana Giannarelli and Massimo Lopez",
year = "2002",
month = "6",
day = "1",
doi = "10.1200/JCO.2002.06.039",
language = "English",
volume = "20",
pages = "2689--2694",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - First-line treatment with epirubicin and vinorelbine in metastatic breast cancer

AU - Vici, Patrizia

AU - Colucci, Giuseppe

AU - Gebbia, Vittorio

AU - Amodio, Antonella

AU - Giotta, Francesco

AU - Belli, Franca

AU - Conti, Francesca

AU - Gebbia, Nicola

AU - Pezzella, Giuseppe

AU - Valerio, Maria Rosaria

AU - Brandi, Mario

AU - Pisconti, Salvatore

AU - Durini, Ernesto

AU - Giannarelli, Diana

AU - Lopez, Massimo

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Purpose: This phase II multicenter trial was aimed at investigating the activity of epirubicin-vinorelbine combination as first-line chemotherapy in metastatic breast cancer patients. Patients and Methods: Ninety-seven patients with metastatic breast cancer and no prior exposure to anthracyclines received the following regimen: epirubicin 100 mg/m2 by intravenous (IV) bolus infusion on day 1 plus vinorelbine 25 mg/m2 by 30-minute IV infusion on days 1 and 5, every 3 weeks for up to eight cycles. All patients also received granulocyte colony-stimulating factor (G-CSF) on days 7 to 12 of every cycle. Results: Objective responses, confirmed at least 4 weeks after the first documentation, were observed in 65 out of 92 assessable patients (70.6%; 95% Cl, 62% to 80%). Disease remained stable in 17 patients (18.5%). Responses were observed in all disease sites, being 94% in soft tissue, 60% in bone, and 66% in visceral disease. Median time to response, median duration of response, median time to progression, and median overall survival were 2, 9, 10, and 26 months, respectively. The dose-limiting toxicity was neutropenia, which was grade 4 in 36% of the patients, and was accompanied by fever in 26% of the cases. Grade 3 to 4 mucositis was encountered in 28% of the patients. Other toxicities were mild to moderate. No cardiotoxicity was observed. Conclusion: The epirubicin-vinorelbine combination with G-CSF support has been shown in this study to be highly active as first-line treatment of metastatic breast cancer patients, with significant although transient toxicity. This justifies further evaluation in the neoadjuvant setting and in early-stage breast cancer.

AB - Purpose: This phase II multicenter trial was aimed at investigating the activity of epirubicin-vinorelbine combination as first-line chemotherapy in metastatic breast cancer patients. Patients and Methods: Ninety-seven patients with metastatic breast cancer and no prior exposure to anthracyclines received the following regimen: epirubicin 100 mg/m2 by intravenous (IV) bolus infusion on day 1 plus vinorelbine 25 mg/m2 by 30-minute IV infusion on days 1 and 5, every 3 weeks for up to eight cycles. All patients also received granulocyte colony-stimulating factor (G-CSF) on days 7 to 12 of every cycle. Results: Objective responses, confirmed at least 4 weeks after the first documentation, were observed in 65 out of 92 assessable patients (70.6%; 95% Cl, 62% to 80%). Disease remained stable in 17 patients (18.5%). Responses were observed in all disease sites, being 94% in soft tissue, 60% in bone, and 66% in visceral disease. Median time to response, median duration of response, median time to progression, and median overall survival were 2, 9, 10, and 26 months, respectively. The dose-limiting toxicity was neutropenia, which was grade 4 in 36% of the patients, and was accompanied by fever in 26% of the cases. Grade 3 to 4 mucositis was encountered in 28% of the patients. Other toxicities were mild to moderate. No cardiotoxicity was observed. Conclusion: The epirubicin-vinorelbine combination with G-CSF support has been shown in this study to be highly active as first-line treatment of metastatic breast cancer patients, with significant although transient toxicity. This justifies further evaluation in the neoadjuvant setting and in early-stage breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036605801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036605801&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.06.039

DO - 10.1200/JCO.2002.06.039

M3 - Article

C2 - 12039931

AN - SCOPUS:0036605801

VL - 20

SP - 2689

EP - 2694

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -